ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis 2Q Net Profit Up Marginally, Beating Expectations

By Marta Falconi ZURICH--Swiss drug maker Novartis AG (NVS) said Thursday its net profit rose slightly in the second quarter, helped by the good performance of its eye care unit and the flagship pharmaceutical division, which helped offset weaker sales of blockbuster drug Diovan, which was hurt by increased generics competition. The Basel-based company said it is on track to deliver 2012 full-year outlook after net profit for the three months to the end of June edged up to $2.71 billion from $2.70 billion in the same period a year earlier, above analysts' expectations of $2.52 billion. Net sales were down 4% at $14.3 billion, hurt by increased competition for the company's generic unit Sandoz and the continued drag from the suspension of production at a factory in Lincoln, Nebraska. Sales at the flagship pharmaceuticals division decreased 1% to $8.3 billion. Write to Marta Falconi at marta.falconi@dowjones.com Order free Annual Report for Novartis AG Visit http://djnweurope.ar.wilink.com/?ticker=CH0012005267 or call +44 (0)208 391 6028 Order free Annual Report for Novartis AG Visit http://djnweurope.ar.wilink.com/?ticker=US66987V1098 or call +44 (0)208 391 6028 Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Novartis (NVS)
DateTimeHeadline
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?
04/23/201518:21:48ADR Shares End Higher; Ericsson Drops, Logitech Rises
04/23/201512:49:55Eli Lilly Results Top Expectations
04/23/201512:44:52Eli Lilly Results Top Expectations
04/23/201512:32:22Novartis Begins to See Benefits of Overhaul -- 2nd Update
04/23/201506:59:03Novartis Begins to See Benefits of Overhaul -- Update
04/23/201503:58:06Novartis Profit Boosted by Disposals
04/23/201502:54:59Novartis Profit Boosted by Disposals
04/22/201519:20:35CSL Says CFO Naylor to Lead Influenza-Vaccine Business
04/22/201510:03:023 Soaring Biotech Stocks Under $10 -- Are They Buys?
04/20/201518:59:29Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed...
04/20/201517:43:06Novartis 1Q 2015 -- Forecast
04/19/201507:14:033 Megatrends in Healthcare
04/18/201509:19:03Meet the Game-Changing Drug Designed to Fight America's Leading...
04/16/201517:15:08Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
04/16/201516:51:37FDA Approves Generic Multiple-Sclerosis Drug by Novartis's Sandoz...
04/16/201516:07:15FDA Approves Novartis and Momenta's Generic Multiple-Sclerosis...
04/16/201508:58:023 Potential Blockbuster Drugs That Could Be Approved Before Year's...
04/15/201508:59:033 Biotech Stocks That May Disappear Before 2020
04/14/201508:44:32The Growing Business Of Animal Healthcare

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad